Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: October 27, 2006
Last updated: March 29, 2012
Last verified: March 2012
Tinnitus associated to hearing loss is a high prevalent audiologic disorder with important unmet needs as far as therapy is concerned. The present study is exploring the possible beneficial effects on tinnitus loudness or annoyance of a combination drug treatment aimed to increase the local inhibitory activity of neural circuitries involved in sound perception and generation. Modest effects have been reported after 8-12 weeks treatment with antidepressants, including high dose paroxetine (up to 50 mg/day). Biologic data suggests that the combination of increase of extracellular serotonin using an SSRI and of blockade of NK1 receptors using a novel NK1 antagonist may lead to a reduced tinnitus and, possibly, improved hearing acuity. To this aim, two 14 day treatment conditions, i.e., SSRI paroxetine (20 mg/day) plus the NK1 antagonist vestipitant (25mg /day) or vestipitant alone (25 mg /day), will be compared to placebo in patients suffering from tinnitus previously selected for their capacity to reliably score the transient attenuation of tinnitus loudness produced by lidocaine infusion. Effects on principal endpoints will be collected within 4 hrs from last administration, when the plasma levels of vestipitant are calculated to be in the range associated to pharmacodynamic effects on VAS anxiety and qEEG (>30 ng/ml). PK, safety and tolerability of the paroxetine-vestipitant combination was addressed with preclinical and Phase I studies, showing no relevant issue. The cross-over study will require approximately 24 patients. Audiometry and computer-based Automated Psychoacoustics will be performed as instrumental endpoints to support subjective scores. A diary will be used at home to score tinnitus severity at home during the study.

Condition Intervention Phase
Drug: Vestipitant
Drug: Vestipitant + Paroxetine
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 14 Days of Vestipitant or Vestipitant / Paroxetine Combination in an Enriched Population of Subjects With Tinnitus & Hearing Loss

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Visual Analog Scales (VAS) to measure the change in tinnitus loudness as perceived at the moment of the measurement at 2 hrs after dosing (or at any other time point vs. pre-dose baseline). [ Time Frame: 2 hrs after dosing (or at any other time point vs. pre-dose baseline). ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • VAS to measure tinnitus pitch, distress and anxiety. Pure Tone Audiometry & Psychoacoustic assessment. Sleep & Tinnitus questionnaires. Safety, tolerability and pharmacokinetics of drug. [ Time Frame: perceived at the moment of the measurement at 2 hrs after dosing (or at any other time point vs. pre-dose baseline). ] [ Designated as safety issue: No ]

Enrollment: 26
Study Start Date: December 2006
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Period 1 Drug: Vestipitant
NK1 receptor antagonist
Drug: Vestipitant + Paroxetine
NK1 receptor antagonist and SSRI
Other Name: Vestipitant
Other: Placebo
Period 2 Drug: Vestipitant
NK1 receptor antagonist
Drug: Vestipitant + Paroxetine
NK1 receptor antagonist and SSRI
Other Name: Vestipitant
Other: Placebo
Period 3 Other: Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Male or female subjects with a diagnosed tinnitus.
  • Subject with THI severity grade of 3 or 4.
  • Subjects willing to restrict alcohol intake.
  • The subject must have given written consent.
  • Women of childbearing potential who abstain from intercourse OR agree to birth control.
  • Women of non-childbearing potential.

Exclusion criteria:

  • Subject with THI severity grade = 5 or less than or equal to 2.
  • Subject with pathologic level of anxiety or depression.
  • Subject with no audiogram deficit and with normal hearing.
  • Subjects that do not respond to the lidocaine infusion test or show a large variability in pre-infusion values.
  • Subjects with any serious medical or surgical condition
  • Subjects positive for drug use and/or a history of substance abuse or dependence.
  • Subjects who have taken psychotropic drugs or antidepressants within specified time frames.
  • Subjects who have recently used an investigational drug or recently participated in a trial.
  • Subjects who have exhibited intolerance to NK1 antagonists or SSRIs.
  • Women who have a positive pregnancy test.
  • Female subjects who intend to get pregnant or male subjects who intend to father a child within the next 4 weeks following the last study drug administration in the study.
  • Subjects, who have donated a unit of blood or more within the previous month or who intend to donate blood within one month of completing the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00394056

United Kingdom
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB2 2GG
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00394056     History of Changes
Other Study ID Numbers: NKP106254 
Study First Received: October 27, 2006
Last Updated: March 29, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
repeated dose
Hearing Loss
vestipitant (GW597599)

Additional relevant MeSH terms:
Hearing Loss
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Neurokinin-1 Receptor Antagonists processed this record on September 29, 2016